50
Chemical resistant diaphragm pumps
The C Series chemical resistant diaphragm pumps from Wiggens are an excellent solution for continuous, oil-free pumping of corrosive gases and vapours and meet demanding applications. The multi-stage construction provides an advantageous combination of high pumping speed and ultimate low vacuum. All major parts in contact with pumped media are made of PTFE which are ideal for extremely aggressive/corrosive gases and vapours. The sealing system provides reduced leakage rates for improved ultimate vacuum (1mbar).
Wiggens is continuously expanding the line of diaphragm pumps and applying new technologies to the C Series. The latest models feature more powerful motor-driven multi- stage pump heads, making them an excellent choice for applications requiring high vacuum levels with corrosive gases and vapours. These pumps find applications in pilot reactors, industrial rotary evaporators, the semiconductor industry, drying ovens, and various laboratory applications. The maximum pumping speed can reach up to 145L/min.
Equipped with a frequency conversion motor, these powerful pumps can achieve high vacuum levels quickly and with good stability, making them suitable for larger laboratory applications.
Furthermore, the frequency conversion vacuum pump helps reduce noise in the laboratory and extends the service life. If you have any questions about vacuum requirements for your experiments, please contact Wiggens for assistance.
More information online:
ilmt.co/PL/v81R 57812pr@reply-direct.com
Enhancing pharmaceutical safety: Microcrystalline cellulose with ultra-low nitrite concentration
Asahi Kasei is advancing pharmaceutical safety by presenting Ceolus™ microcrystalline cellulose (MCC) with nitrite levels reduced to 0.1 μg/g (ppm) or less. This initiative aims to contribute to minimising the potential risk of carcinogenic nitrosamine impurities in pharmaceuticals and nutritional supplements.
In response to the detection of potentially carcinogenic nitrosamine impurities in pharmaceuticals in 2018, there has been a global increase in awareness regarding the health risks associated with nitrosamine. Aligning with guidelines from authoritative bodies such as the European Medicines Agency (EMA) and the US Food & Drug Administration (FDA), the pharmaceutical industry has been actively investigating and addressing the factors contributing to nitrosamine impurities. Nitrosation, a reaction involving secondary or tertiary amines with nitrites during or post the drug manufacturing process, is identified as a key risk factor. Reducing nitrite concentrations in pharmaceutical raw materials stands out as a crucial strategy for mitigating the risk of nitrosamine formation.
Ceolus™, Asahi Kasei’s MCC produced in Nobeoka, Miyazaki, Japan since 1970, primarily serves as an excipient in pharmaceuticals, nutritional supplements, and foods. Recognised for its application as a tablet binder, especially in high-performance formulations, Ceolus™ contributes to overcoming tableting challenges and creating distinctive and patient-friendly dosage forms. Asahi Kasei has succeeded in maintaining the nitrite concentration in various grades of Ceolus™ at 0.1 ppm or less, underscoring its commitment to delivering safer pharmaceuticals and nutritional supplements.
Hideyuki Kimura, Senior General Manager of Asahi Kasei’s Healthcare Materials Division overseeing Ceolus™, emphasised: “Controlling the nitrite concentration in our products is an important step to ensure the provision of safer pharmaceuticals and nutritional supplements. We will continue to work on further improvements and emphasise the importance of reducing the risk of nitrosamine impurities.”
Additionally, in January 2024, Asahi Kasei commenced full commercial operations of its second Ceolus™ manufacturing facility at Mizushima Works in Okayama Prefecture, Japan. This strategic move not only increases supply capacity but also enhances supply chain stability through dual-site production.
More information online:
ilmt.co/PL/nm60 62201pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
